Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 3/20 | 0.38 |
| ▸ | KCNQ2 | O43526 | 3/20 | 0.38 |
| ▸ | KCNQ4 | P56696 | 2/20 | 0.38 |
| ▸ | KCNQ5 | Q9NR82 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 10/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.33 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.31 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21611529 | 1.00 | KCNQ3 (0.38) | KCNQ3KCNQ2KCNQ4KCNQ5POLB | |
| SCHEMBL21611532 | 1.00 | KCNQ3 (0.38) | KCNQ3KCNQ2KCNQ4KCNQ5POLB | |
| SCHEMBL22492105 | 0.81 | KCNQ3 (0.53) | KCNQ3KCNQ2KCNQ4KCNQ5POLB | |
| SCHEMBL22492099 | 0.81 | KCNQ3 (0.53) | KCNQ3KCNQ2KCNQ4KCNQ5POLB | |
| SCHEMBL22492104 | 0.81 | KCNQ3 (0.53) | KCNQ3KCNQ2KCNQ4KCNQ5POLB | |
| SCHEMBL22492042 | 0.77 | KCNQ3 (0.41) | KCNQ3KCNQ2KCNQ4KCNQ5POLB | |
| SCHEMBL22492037 | 0.77 | KCNQ3 (0.41) | KCNQ3KCNQ2KCNQ4KCNQ5POLB | |
| SCHEMBL22492040 | 0.77 | KCNQ3 (0.41) | KCNQ3KCNQ2KCNQ4KCNQ5POLB | |
| SCHEMBL2037988 | 0.76 | SLC6A2 (0.38) | KCNQ3KCNQ2POLBADORA2BGRM2 | |
| SCHEMBL22492046 | 0.76 | POLB (0.36) | KCNQ3KCNQ2KCNQ4KCNQ5POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11332472-B2 | Substituted piperidines as inhibitors of ubiquitin specific protease 7 | LES LABORATOIRES SERVIER (FR) | 2022-05-17 | — | — | US | disclosed |
| US-20210221785-A1 | AMINO-PYRIMIDONYL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | VERNALIS (R&D) LTD (GB) | 2021-07-22 | — | — | US | disclosed |
| EP-3818054-A1 | AMINO-PYRIMIDONYL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Les Laboratoires Servier (FR) | 2021-05-12 | — | — | EP | disclosed |
| CN-112368276-A | Amino-pyrimidinone derivatives, process for their preparation and pharmaceutical compositions containing them | 法国施维雅药厂 | 2021-02-12 | — | — | CN | disclosed |
| US-20200407363-A1 | NEW PIPERIDINYL DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | LES LABORATOIRES SERVIER (FR) | 2020-12-31 | — | — | US | disclosed |
| EP-3717482-A1 | NEW PIPERIDINYL DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | Les Laboratoires Servier SAS (FR) | 2020-10-07 | — | — | EP | disclosed |
| CN-111542524-A | Novel piperidinyl derivatives as inhibitors of ubiquitin-specific protease 7 | 法国施维雅药厂 | 2020-08-14 | — | — | CN | disclosed |
| WO-2020008013-A1 | AMINO-PYRIMIDONYL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2020-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11332472-B2 | Substituted piperidines as inhibitors of ubiquitin specific protease 7 | USP7, PSMA7, PSMB7 | KCNQ3 4231/4885KCNQ2 3921/4885KCNQ4 4466/4885 |
| US-20210221785-A1 | AMINO-PYRIMIDONYL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DHFR, QDPR, DPYD | KCNQ3 914/4885KCNQ2 766/4885KCNQ4 1112/4885 |
| US-20200407363-A1 | NEW PIPERIDINYL DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | PSMB7, PSMA7, USP7 | KCNQ3 4378/4885KCNQ2 3943/4885KCNQ4 4511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.